STOCK TITAN

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
NeoGenomics, Inc. (NASDAQ:NEO) will participate in the Piper Sandler 35th Annual Global Healthcare Conference in New York City. Members of NeoGenomics' management team will engage in a fireside chat on November 29th at 9:00 a.m. Eastern Time. A live and archived audio webcast of the presentation will be accessible on the company's Investor Relations website.
Positive
  • None.
Negative
  • None.

FT. MYERS, FL / ACCESSWIRE / November 14, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the company will participate in the upcoming Piper Sandler 35th Annual Global Healthcare Conference in New York City.

Members of NeoGenomics' management team will participate in a fireside chat on Wednesday, November 29th at 9:00 a.m. Eastern Time. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company's website at ir.neogenomics.com.

About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Investor Contact

Kendra Sweeney
239-877-7474
kendra.sweeney@neogenomics.com

Media Contact

Lisa Whitmyer
216-513-7808
lisa.whitmyer@neogenomics.com

SOURCE: NeoGenomics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/802688/neogenomics-to-participate-at-the-piper-sandler-35th-annual-healthcare-conference

NeoGenomics, Inc. is participating in the Piper Sandler 35th Annual Global Healthcare Conference.

The fireside chat will take place on Wednesday, November 29th at 9:00 a.m. Eastern Time.

The webcast will be available on the 'News, Events, and Webcasts' tab via the Investor Relations section of the Company's website at ir.neogenomics.com.
Neogenomics Inc.

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Stock Data

Testing Laboratories
Professional, Scientific, and Technical Services
Link
Health Services, Medical/Nursing Services, Professional, Scientific, and Technical Services, Testing Laboratories
US
Fort Myers

About NEO

neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig